

Form PTO-1449 U.S. Department of Commerce

(REV. 8-83) Patent and Trademark Office

Atty. Docket No.
ENZ-64(D3)

Serial No. 10/733,488

INFORMATION DISCLOSURE CITATION
(use several sheets if necessary)

Applicants: Ilan, et al

Filed: Dec. 10, 2003

Group: ~~Not yet assigned~~
1648

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPRO- PRIATE
	10	3	7	7	6	2	8			Roy-Chowdhury, et al			3/4/03
		0	1	7	0	2	5	8	9/11/03	Roy-Chowdhury, et al	A1		

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	TRANSLATION YES NO	
ele	EP	1	0	7	2	2	7	1	1/31/01	Rabbani, et al	A2			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

ele		Schoenfeld, Y., et al, "Gaucher's disease: a disease with chronic stimulation of the immune system," Arch Pathol Lab Med 106(8):388-391 (1982)
		Lichtenstein, et al, "Cytokine mRNA in Gaucher Disease," Blood Cells, Molecules and Diseases 23(19):395-401 (1997)
		Barak, V., et al, "Cytokines in Gaucher's Disease," Eur. Cytokine Netw. 10(2):205-210 (1999)
		Hollak, CEM, et al, "Elevated Levels of M-CSF, sCD14 and IL8 in Type 1 Gaucher Disease," Blood Cells, Molecules and Diseases 23(11):201-212 (1997)
		Allen, MJ, et al, "Pro-inflammatory cytokines and the pathogenesis of Gaucher's disease: increased release of interleukin-6 and interleukin-10," Q. J. Med. 90(1):19-25 (1997)
		Deibener, J., et al, "Enzyme replacement therapy decreases hypergammaglobulinemia in Gaucher's disease," Haematologica 83:479-480 (1998)
		Lachman, et al, "Massive hepatic fibrosis in Gaucher's disease: clinico-pathological and radiological features," Q. J. Med 93:237-244 (2000)
		Kawano, et al, "CD1d-Restricted and TCR-Mediated Activation of V _α 14 NKT Cells by Glycosylceramides," Science 278:1626-1629 (1997)
		Burdin, N., et al, "Selective Ability of Mouse CD1 to Present Glycolipids: α -Galactosylceramide Specifically Stimulates V _α 14 ⁺ NK T Lymphocytes," J. Immunol 161:3271-3281 (1998)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce

(REV. 8-83) Patent and Trademark Office

INFORMATION DISCLOSURE CITATION

(use several sheets if necessary)

Atty. Docket No.
ENZ-64(D3)


Serial No. 10/733,488

Applicants: Ilan, et al

Filed: Dec. 10, 2003

Group: ~~Not yet assigned~~

Att: 1648



U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPRO- PRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	TRAN- SLATION YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

ele	Hollak, et al, "Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease," J. Clin. Invest. 93(3):1288-1292 (1994)
	Ferrari, C., et al, "Immunopathogenesis of hepatitis C virus infection," J. Hepatol 31s1:31-38 (1999)
	Cerny, A., et al, "Pathogenesis of chronic hepatitis C: immunological features of hepatic injury and viral persistence," Hepatology 30(3):595-601 (1999)
	Rehermann, B., "Cellular immune response to the hepatitis C virus," J. Viral Hepat. 6s1:31-35 (1999)
	Gotsman, I., et al, "Induction of oral tolerance towards hepatitis B envelope antigens in a murine model," Antiviral Research 48:17-26 (2000)
	Akbar, SM, et al, "Low responsiveness of hepatitis B virus-transgenic mice in antibody response to T-cell-dependent antigen: defect in antigen presenting activity of dendritic cells," Immunology 78(3):468-475 (1993)

EXAMINER

DATE CONSIDERED

Carlyle

2/18/06

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce
(REV. 8-83) Patent and Trademark Office

Atty. Docket No.
ENZ-64(D3)


Serial No. 10/733,488

INFORMATION DISCLOSURE CITATION
(use several sheets if necessary)

Applicants: Ilan, et al

Filed: Dec. 10, 2003

Group: 1648



U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPRO- PRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	TRAN- SLATION YES NO
<i>elc</i>	WO	9 9 3 3 4 7 5	7/8/99	Fredman, et al	A1		
	EP	0 9 5 7 1 6 1	11/17/99	Koezuka, et al	A1		
	EP	0 9 8 8 8 6 0	3/29/00	Taniguchi, et al	A1		
	WO	0 3 9 3 2 8 7	11/13/03	Vo-Hoang, et al	A1		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>elc</i>	Margalit, M., et al., "Glucocerebroside Treatment Ameliorates Con-A Hepatitis by Inhibition of NKT Lymphocytes: A New Immunomodulatory Tool," Hepatology 38:163A (2003)

EXAMINER

Emily Lee

DATE CONSIDERED

2/14/06

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.